Resources from the same session
LBA41 - Nivolumab (nivo) ± ipilimumab (ipi) in pre-treated patients with advanced, refractory pulmonary or gastroenteropancreatic poorly differentiated neuroendocrine tumors (NECs) (GCO-001 NIPINEC)
Presenter: Thomas Walter
Session: Proffered Paper session - NETs and endocrine tumours
Resources:
Abstract
Slides
Webcast
1098O - Nivolumab plus platinum-doublet chemotherapy as first-line therapy in unresectable, locally advanced or metastatic G3 neuroendocrine Neoplasms (NENs) of the gastroenteropancreatic (GEP) tract or unknown (UK) origin: Preliminary results from the phase II NICE-NEC trial (GETNE T1913)
Presenter: Maria Carmen Riesco-Martinez
Session: Proffered Paper session - NETs and endocrine tumours
Resources:
Abstract
Slides
Webcast
1096O - Lanreotide autogel/depot (LAN) in patients with advanced bronchopulmonary (BP) neuroendocrine tumors (NETs): Results from the phase III SPINET study
Presenter: Dieter Horsch
Session: Proffered Paper session - NETs and endocrine tumours
Resources:
Abstract
Slides
Webcast
1097O - The AXINET trial (GETNE1107): Axitinib plus octreotide LAR improves PFS by blinded central radiological assessment vs placebo plus octreotide LAR in G1-2 extrapancreatic NETs
Presenter: Rocio Garcia-Carbonero
Session: Proffered Paper session - NETs and endocrine tumours
Resources:
Abstract
Slides
Webcast
Q&A and live discussion
Presenter: Nicola Fazio
Session: Proffered Paper session - NETs and endocrine tumours
Resources:
Slides
Webcast
Q&A and live discussion
Presenter: Angela Lamarca
Session: Proffered Paper session - NETs and endocrine tumours
Resources:
Slides
Webcast
Invited Discussant LBA41
Presenter: Angela Lamarca
Session: Proffered Paper session - NETs and endocrine tumours
Resources:
Slides
Webcast